Low-energy electron diffraction patterns contain precise information about the structure of the surface studied. However, retrieving the real space lattice periodicity from complex diffraction patterns is challenging, especially when the modeled patterns originate from superlattices with large unit cells composed of several symmetry-equivalent domains without a simple relation to the substrate. This work presents ProLEED Studio software, built to provide simple, intuitive and precise modeling of low-energy electron diffraction patterns. The interactive graphical user interface allows real-time modeling of experimental diffraction patterns, change of depicted diffraction spot intensities, visualization of different diffraction domains, and manipulation of any lattice points or diffraction spots. The visualization of unit cells, lattice vectors, grids and scale bars as well as the possibility of exporting ready-to-publish models in bitmap and vector formats significantly simplifies the modeling process and publishing of results.

A systematic procedure is introduced for modeling charge-neutral non-polar surfaces of ionic minerals containing polyatomic anions. By integrating distance- and charge-based clustering to identify chemical species within the mineral bulk, our pipeline, PolyCleaver, renders a variety of theoretically viable surface terminations. As a demonstrative example, this approach was applied to forsterite (Mg2SiO4), unveiling a rich interface landscape based on interactions with formaldehyde, a relevant multifaceted molecule, and more particularly in prebiotic chemistry. This high-throughput method, going beyond techniques traditionally applied in the modeling of minerals, offers new insights into the potential catalytic properties of diverse surfaces, enabling a broader exploration of synthetic pathways in complex mineral systems.

Proteins are well known `shapeshifters' which change conformation to function. In crystallography, multiple conformational states are often present within the crystal and the resulting electron-density map. Yet, explicitly incorporating alternative states into models to disentangle multi-conformer ensembles is challenging. We previously reported the tool FLEXR, which, within a few minutes, automatically separates conformational signal from noise and builds the corresponding, often missing, structural features into a multi-conformer model. To make the method widely accessible for routine multi-conformer building as part of the computational toolkit for macromolecular crystallography, we present a graphical user interface (GUI) for FLEXR, designed as a plugin for Coot 1. The GUI implementation seamlessly connects FLEXR models with the existing suite of validation and modeling tools available in Coot. We envision that FLEXR will aid crystallographers by increasing access to a multi-conformer modeling method that will ultimately lead to a better representation of protein conformational heterogeneity in the Protein Data Bank. In turn, deeper insights into the protein conformational landscape may inform biology or provide new opportunities for ligand design. The code is open source and freely available on GitHub at https://github.com/TheFischerLab/FLEXR-GUI.

The strong metal–support interaction (SMSI) is a phenomenon observed in supported metal catalyst systems in which reducible metal oxide supports can form overlayers over the surface of active metal nanoparticles (NPs) under a hydrogen (H2) environment at elevated temperatures. SMSI has been shown to affect catalyst performance in many reactions by changing the type and number of active sites on the catalyst surface. Laboratory methods for the analysis of SMSI at the nanoparticle-ensemble level are lacking and mostly based on indirect evidence, such as gas chemisorption. Here, we demonstrate the possibility to detect and characterize SMSIs in Co/TiOx model catalysts using the laboratory X-ray standing wave (XSW) technique for a large ensemble of NPs at the bulk scale. We designed a thermally stable MoNx/SiNx periodic multilayer to retain XSW generation after reduction with H2 gas at 600°C. The model catalyst system was synthesized here by deposition of a thin TiOx layer on top of the periodic multilayer, followed by Co NP deposition via spare ablation. A partial encapsulation of Co NPs by TiOx was identified by analyzing the change in Ti atomic distribution. This novel methodological approach can be extended to observe surface restructuring of model catalysts in situ at high temperature (up to 1000°C) and pressure (≤3 mbar), and can also be relevant for fundamental studies in the thermal stability of membranes, as well as metallurgy.

A deep-learning algorithm is proposed for the inpainting of Bragg coherent diffraction imaging (BCDI) patterns affected by detector gaps. These regions of missing intensity can compromise the accuracy of reconstruction algorithms, inducing artefacts in the final result. It is thus desirable to restore the intensity in these regions in order to ensure more reliable reconstructions. The key aspect of the method lies in the choice of training the neural network with cropped sections of diffraction data and subsequently patching the predictions generated by the model along the gap, thus completing the full diffraction peak. This approach enables access to a greater amount of experimental data for training and offers the ability to average overlapping sections during patching. As a result, it produces robust and dependable predictions for experimental data arrays of any size. It is shown that the method is able to remove gap-induced artefacts on the reconstructed objects for both simulated and experimental data, which becomes essential in the case of high-resolution BCDI experiments.

PayComplete has unveiled a report that...

The dangerous Delta variant of the coronavirus is spreading so quickly in the United States that it's likely the mutant strain will become predominant in the U.S. within weeks, according to a new analysis.

The variant, first identified in India, is the most contagious yet and, among those not yet vaccinated, may trigger serious illness in more people than other variants do, say scientists tracking the spread of infection.

The Delta variant apparently already accounts for at least 14% of all new infections, according to the research analysis posted online Monday of more than 242,000 infections nationwide over the last six months.

Another reason to get vaccinated

"It definitely is of concern," says William Lee, the vice president of science at Helix, which is under contract with the Centers for Disease Control and Prevention to help track the variants.

"Just the fact that it's so transmissible means that it's it's dangerous," Lee says, "and so I think you'll see outbreaks of Delta around the country and more people will get sick from it."

Helix launched the study when researchers spotted a drop in the prevalence of the Alpha variant, a contagious strain first spotted in the U.K. that had quickly become the dominant variant in that country and the U.S.

The researchers discovered the drop in relative frequency of the Alpha variant in their spot checks of strains circulating in the U.S. was due to a rapid increase in two other variants: the Gamma variant, first spotted in Brazil, and the Delta variant. The Gamma variant may be slightly better than the original strain at outmaneuvering the vaccines, researchers say.

"It looks like both of them are going to slowly push out Alpha," says Lee, whose study has not yet been peer-reviewed but has been posted on a pre-print server.

How Delta could prompt another U.S. COVID-19 surge

All the vaccines authorized for use in the U.S. appear, in general, to provide powerful protection against all the variants, including Delta. But the rapid spread of the variants is still raising concern because of the large number of people who remain unvaccinated.

"There still are big portions of the country where the rates of vaccination are quite low," notes Dr. Jeremy Luban, a virologist at the University of Massachusetts Medical School. "And, in fact, the Helix paper shows that this Delta variant is increasing in frequency — the speed at which it's increasing in frequency is greatest in those areas where vaccination rates are lowest."

The Delta variant could trigger yet another moderate surge of infections through many parts of the U.S. because of these pockets of unvaccinated people, according to a recent set of projections from the COVID-19 Scenario Modeling Hub, which is helping the CDC plot the future course of the pandemic.

The projections indicate that infections could start to rise again as soon as some time in July, especially if the vaccination campaign continues to stall.

"For the most part, it's a moderate resurgence," says Justin Lessler, an epidemiologist at Johns Hopkins University who is helping coordinate the hub.

"We're not having massive epidemics at a national level, but we have this kind of continuation of the virus just sticking around and keeping us on our toes," Lessler says. "And in specific places there could be substantial epidemics still."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Moderna says recently completed studies have found its vaccine to have a neutralizing effect against all COVID-19 variants tested, including the delta variant.; Credit: Fred Tanneau/AFP via Getty Images

Studies have found that Moderna's COVID-19 vaccine is effective against several variants of concern, including the delta variant, the biotech company announced.

Moderna said Tuesday that recently completed studies have found the vaccine to have a neutralizing effect against all COVID-19 variants tested, including the beta, delta, eta and kappa variants.

While still highly effective against the delta variant, the study showed the vaccine was less effective against it and certain other variants than against the original strain of the virus.

The antibody response against the delta variant was about two times weaker than against the ancestral strain of the virus.

The news echoes other findings that the Moderna and Pfizer vaccines are highly effective against the delta variant. A study published this month in Nature found that Pfizer's vaccine was able to neutralize variants including delta, though at somewhat reduced strength.

"These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants," Stéphane Bancel, Moderna's chief executive officer, said in a statement. "These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine."

The company also said it is developing a booster candidate: a 50-50 mix of its currently authorized COVID-19 vaccine and another messenger RNA vaccine it has developed.

The delta variant is spreading fast

The delta variant is the fast-moving form of the coronavirus that is now found in 96 countries, including the United States.

Last week, Dr. Anthony Fauci of the National Institutes of Health said the delta variant is "currently the greatest threat in the U.S. to our attempt to eliminate COVID-19," noting that the proportion of infections being caused by the variant is doubling every two weeks.

The delta variant is now infecting at least 1 out of every 5 people who get the virus in the United States. In some sections of the country, the variant is already far more common, particularly in parts of the Midwest and West. At its current pace, the delta variant is expected to be the dominant virus in the U.S. within weeks.

Dr. Maria Van Kerkhove, an infectious disease expert at the World Health Organization, called the delta variant "incredibly transmissible."

"These viruses are becoming more fit. The virus is evolving, and this is natural," she told NPR's Morning Edition. "It's more transmissible than the alpha variant, so we need to just do all we can to prevent as many infections as we can and do what we can do to reduce the spread."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Detail of boxes with the U.S. donated Johnson & Johnson vaccine against Covid-19 at Universidad de Baja California on June 17, 2021 in Tijuana, Baja California. ; Credit: Francisco Vega/Getty Images

In our continuing series looking at the latest medical research and news on COVID-19, Larry Mantle speaks with Dr. Annabelle De St. Maurice from University of California Los Angeles/Mattel Children’s hospital.

Topics today include:

• J&J says its vaccine is effective against Delta variant

  • J&J vaccine lasts at least 8 months

• WHO says all vaccines it authorized should be recognized by reopening countries

• White House says it will miss July 4 vaccination goal

• Postpartum depression on the rise during the pandemic

• Experts believe Novavax may play a role in combating vaccine hesitancy

• Delta variant is not driving a surge in hospitalization rates in England

Guest: 

Annabelle De St. Maurice, M.D., assistant professor of pediatrics in the division of infectious diseases and the co-chief infection prevention officer at University of California Los Angeles/Mattel Children’s hospital; she tweets @destmauricemd

This content is from Southern California Public Radio. View the original story at SCPR.org.

In this photo taken on February 10, 2020 a 'love kit' is seen on the bed in a room at the Dragonfly hotel in Mumbai.; Credit: PUNIT PARANJPE/AFP via Getty Images

A new survey shows that in the era of widespread vaccine availability, American couples are more satisfied in their relationships -- and some are even getting more experimental than they have been.

Led by Indiana University Kinsey Institute researcher Justin Lehmiller in collaboration with the website Lovehoney, which describes itself as “global sexual happiness experts,” the report looked at responses from 2,000 U.S. adults age 18-45, including an oversample of 200 who identified as LGBTQ, and among the major findings of the survey were that more than half (51 percent) of respondents said their sexual interests had changed during the pandemic, and many of those said they’d started trying things they hadn’t before. It also found that 44 percent of people surveyed said they were communicating better with their partner, and among singles surveyed 52 percent say they’re less interested in casual sex and more than a third of them said they weren’t interested in having sex on the first date.

Today on AirTalk, we’ll talk with Professor Lehmiller about the survey, its findings and how the pandemic impacted Americans’ views on relationships and sex.

Guest: 

Justin Lehmiller, social psychologist and research fellow at Indiana University’s Kinsey Institute who conducted the “Summer of Love” survey; author of “Tell Me What You Want: The Science of Sexual Desire and How It Can Help You Improve Your Sex Life” (Hachette Go, July 2020); host of the “Sex and Psychology” podcast; he tweets @JustinLehmiller

This content is from Southern California Public Radio. View the original story at SCPR.org.

Don't fear the 'shrooms.; Credit: /iStockphoto.com

California on Tuesday moved another step closer to decriminalizing psychedelics — amid a debate over whether their prohibition is an outdated remnant of the War on Drugs — after the author removed a substance (ketamine) from the bill that opponents said can be used as a date-rape drug.

The bill would allow those 21 and older to possess for personal use and “social sharing” psilocybin, the hallucinogenic component of so-called magic mushrooms. It also covers psilocybin, dimethyltryptamine (DMT), ibogaine, mescaline excluding peyote, lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA, often called ecstasy).

The bill bars sharing with those under age 21 or possessing the substances on school grounds. It would remove the state’s ban on cultivating or transferring mushroom spores or other material containing psilocybin or psilocybin.

Even if California makes the bill law, the drugs would still be illegal under federal law.

With files from the Associated Press.

Guests:

Scott Wiener, author of SB 519; California State Senator representing Senate District 11, which includes all of the city and county of San Francisco, Broadmoor, Colma, Daly City, and part of South San Francisco; he tweets @Scott_Wiener

John Lovell, legislative director of the California Narcotics Officers Association

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports 10/28/2024

Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XERTA) and its Cell Pouch technology could be the solution to existing challenges involving the delivery of medical treatments to patients, such as the ones described here.

Diabetic patients in resource-limited settings are having to revert back to one of the less favored, alternative ways to take insulin, via syringes or glass vials, because Danish pharmaceutical company, Novo Nordisk A/S (NVO:NYSE), will stop making its insulin pens, The Guardian reported. Patients generally prefer this method for dosing themselves with insulin, as shown in a 2024 survey, because it is more convenient and more accurate.

Type 1 diabetic patients already are being impacted as Novo stopped supplying its insulin pens to certain regions, South Africa for instance. Patients there have switched back to using glass vials.

In a second situation, Novo Nordisk is working to bring stem cell-based therapies to patients more efficiently and, in seeking a solution, formed a partnership with Evotec SE (EVO:NASDAQ) to develop technologies that will achieve this, noted Evotec is a Germany-based global biotech firm with its own cell therapy and partnered cell types all in preclinical development for various indications, including diabetes, oncology, cardiology, and ophthalmology.

Per the agreement, Novo Nordisk is to provide research and development funding and potentially monetary incentives to Evotec, and Evotec is to develop the desired new technologies. Novo has the option to obtain exclusive rights to use, in a predefined medical indication, the product(s) born out of this collaboration agreement. Novo's areas of focus, along with diabetes, are cardiovascular diseases, rare diseases, growth hormone-related diseases, hemophilia, nonalcoholic steatohepatitis, and weight management.

Safe, Effective Therapeutic Cell Delivery

Sernova Corp.'s Cell Pouch is a vehicle for delivering various types of therapeutic cells to patients, such as donor islet cells to insulin-dependent diabetics.

When used, the Cell Pouch's containment channels are filled with the appropriate therapeutic cells, and then the device is implanted in the patient. In situ, the cells release therapeutic proteins or hormones the patient's body completely or partially lacks. The device creates a vascularized, organ-like environment that protects the therapeutic cells from immune system attacks, keeping them alive and functioning.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote in a Sept. 12 research report.

Sernova is testing its Cell Pouch in the clinic, specifically in Type 1 diabetes. In its ongoing Phase 1/2 study, the Canadian company is evaluating the treatment of insulin-dependent diabetes with donor islets implanted via the Cell Pouch, with added immunosuppression therapy. Study data so far have shown the Cell Pouch to be safe and well tolerated and the treatment, effective, reported Dr. Joseph Pantginis, analyst at H.C. Wainwright & Co., in a Sept. 12 research report.

Seven patients, all six of Cohort A and one in Cohort B, achieved sustained insulin independence, between 5.5 and 50 months in duration, free of hypoglycemic episodes. Their blood sugar levels were controlled in the nondiabetic range (i.e.,) HbA1c less than 6.5%.

"The Cell Pouch is the most advanced encapsulation device in development," Ventum Capital Markets Analyst Stefan Quenneville wrote.

A Cell Pouch removed from one of the study patients showed it still contained functioning insulin, glucagon, and somatostatin-producing cells. No evidence was seen of detrimental fibrotic tissue, too many T-cells, material degradation, or changes in the device architecture.

"We believe the impressive response rates and observed durability support Sernova's strategy and justify further investigation while positioning the technology for potential commercial success," noted Pantginis.

The results add to an expanding collection of evidence that the Cell Pouch is functioning as it should. The data also support the "impressive" results already reported from this study and help derisk future related trials.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund in a Sept. 16 note.

In another of its programs, Sernova, in collaboration with Evotec, is developing an implantable off-the-shelf, induced pluripotent stem cell (iPSC)-based islet replacement therapy, Maund reported.

"This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2)," he added.

This partnership was announced on May 17, 2022. You can read more about it in the press release here.

Market Growth Predicted to 2030

The global live cell encapsulation market, encompassing drug delivery, regenerative medicine and cell transplantation, is expected to continue growing through at least 2030, according to Grand View Research. The market's value, US$210.7 million in 2022, is forecasted to increase at a 3.97% compound annual growth rate between that year and 2030.

"If Sernova is successful in bringing its functional cure for insulin-dependent diabetes to the stage where it can go into commercial production, the global market for it will be massive," wrote Technical Analyst Clive Maund.

Along with diabetes, live cell encapsulation is being used to treat neurological disorders like Parkinson's disease, The market research firm noted. Further, it has been proven to be a suitable way to deliver treatment for other types of diseases, including cancer, anemia, heart failure and more.

Several factors are expected to keep driving market growth during the forecast period, Grand View noted. A significant one is the increasing use of live cell encapsulation in regenerative medicine to replace disease or damaged tissues. A related contributor is rising public and private funding and investments in cell and gene therapies.

The advantages of live cell encapsulation in controlled drug delivery are boosting the market, too. They include enhanced therapeutic effects, lowered drug dose, reduced cytotoxicity, improved patient convenience and better patient compliance.

Novel new products and technological advancements are expected to add value to the market as well.

The Catalysts: Progress With Programs

Various potential stock-moving events are slated for Sernova, according to its September 2024 Corporate Presentation.

Two catalysts are expected by Sernova in 2025, related to the company's ongoing Phase 1/2 clinical trial in Type 1 diabetes. One is results for the remaining Cohort B patients. The other is commencement of Cohort C, who will receive, along with the islet cells, an optimized immune suppression regimen.

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

Next year, Sernova plans to start a Phase 1/2 trial of the regeneratively produced islet cells to result from its partnership with Evotec, delivered via the Cell Pouch to Type 1 diabetes patients.

Other catalysts are expected to come as a result of Sernova advancing its preclinical programs. One is a personalized treatment with patient corrected cells via Cell Pouch for hypothyroidism. Another is a Cell Pouch-delivered, ex vivo lentiviral factor VIII gene therapy for hemophilia, being developed in partnership with the European Haemacure Consortium.

Also, through partnerships, Sernova is developing technologies that would eliminate the need for concurrent immunosuppression during Cell Pouch-delivered cell treatment, a "blue sky objective," Douglas Loe, a Leede Financial Inc. analyst, noted in a Sept. 12 research report.

"Any advances in this regard could be incorporated into future Cell Pouch studies," he wrote. "We do not consider the need for such therapy to be relevant to Cell Pouch function itself."

Analyst: Company is "Very Undervalued"

Several analysts are bullish on Sernova. One of them is Loe, who rates it as a Speculative Buy. His price target on the life sciences firm implies a 455% return from its current share price.

According to H.C. Wainwright's Pantginis, the deepening responses of Type 1 diabetes patients in its Phase 1/2 trial continue to "crystallize Sernova stock's possible upside." The upside reflected in Pantginis' price target is 2,122%. The analyst recommends the company as a Buy.

Ventum's Quenneville also has a Buy on Sernova, and his target price reflects an 826% return on investment. In his report, the analyst highlighted the impressive efficacy and tolerability of the Cell Pouch up to five years post-implantation, as shown in the Phase 1/2 clinical trial data.

"This represents the longest-lasting implanted encapsulation device containing functioning islets without fibrosis," Quenneville wrote.

According to Technical Analyst Maund, Sernova is "very undervalued here given its huge potential" in the Type 1 diabetes market, as indicated on the stock charts. The fundamental outlook for the company is improving, and evidence is strong that a reversal to the upside may be happening. SVA may appreciate significantly soon. [OWNERSHIP_CHART-4790]

"Sernova is therefore viewed as a good stock to accumulate in this area, between the current price and recent lows," Maund wrote on Sept. 16. At that time, Sernova's share price was about the same as it is now.

Ownership and Share Structure

According to Refinitiv, about 12.96% of the company is held by insiders and management, and 0.05% by institutions. The rest is retail.

Top shareholders include Tomas Angel with 4.91%, Director Steven Sangha with 4.27%, Betty Anne Millar with 1.32%, Brett Alexander Whalen with 0.87%, and Garry Deol with 0.77%.

Its market cap is CA$83 M. Its 52-week range is CA$0.20−0.82 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Sernova Corp. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Corp.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: SVA:TSX.V;SEOVF:OTCQB;PSH:XERTA, )

Halima Aden attends the premiere of Netflix's Travis Scott: Look Mom I Can Fly at Barker Hangar on Aug. 27, 2019, in Santa Monica, Calif.; Credit: Rich Fury/Getty Images

For Halima Aden, the decision to walk away from a career as the world's first hijab-wearing supermodel was fairly clear cut. She's felt used for so long, she says — by the modeling industry and by UNICEF, the organization she was photographed by as a child in a refugee camp in Kenya and later served as an ambassador for.

Aden has been featured on the covers of Vogue, Elle and Allure magazines. And she walked the runway for Rihanna's Fenty Beauty and Kanye West's Yeezy.

She tells Morning Edition host Rachel Martin she wanted to be a role model for young girls while being true to herself, but she wasn't accomplishing either. Modeling, she realized, was in "direct conflict" with who she is.

"I'm not a cover girl, I'm Halima from Kakuma," she says. "I want to be the reason why girls have confidence within themselves, not the reason for their insecurity."

Aden was raised in the Kakuma refugee camp in northwestern Kenya. She and her family moved to Minnesota in 2004 when she was 7.

It was there her journey as a model began, competing for Miss Minnesota USA in 2016, seeking a scholarship. She finished in the semifinals, and says from there, modeling "fell from the sky" into her lap.

Interview Highlights

You saw [modeling] not just as a chance to wear gorgeous clothes and to have your photo in magazines but also as a way to help people.

Growing up in America, not seeing representation, not seeing anybody who dressed like me look like me, it did make me feel like, wow, what's wrong with me, you know? And I'm sure if I had if I would have had representation growing up, I would have been so much more confident to wear my hijab, to be myself, to be authentic. But to be that person, to grow up and be on the cover of magazines, I've covered everything from Vogue to Allure, some of the biggest publications in fashion. And yet I still couldn't relate personally to my own image because that's not who I really am. That's not how I really dress. That's not how my hijab really looks. And, you know, fashion, it can be a very creative field, and I completely appreciate that. But my hijab was just getting spread so thin that I knew I had to give it all away, give it up. I'm not a cover girl. I am Halima from Kakuma. I want to be the reason why girls have confidence within themselves, not the reason for their insecurity.

When you say your hijab was being kind of styled out of existence, what passed for a hijab as you were walking down those runways?

Everything. Oh, my goodness. I had jeans at one point on my head as a hijab. I had Gucci pants styled as a turban. It just didn't even make sense, and I felt so far removed from the image itself.

During the pandemic you decided to walk away from fashion and UNICEF. Was it a complicated decision?

I'll be honest with you, the feelings that I've had towards the fashion industry and UNICEF, it was just multiplying as the years went on, so it was just festering. You know, because the fashion industry is very known to use these young girls and boys while their young, age 14 to like 24, I think is the average career of a model. And then they just replace them and move on to a newer model. And same with UNICEF. They've been photographing me and using me since the time I was a baby in a refugee camp. I remember getting those headshots taken and it made me feel, it's very dehumanizing. And so I wanted to show UNICEF, too. How does it feel to be used? It's not a good feeling. And so let's stop using people.

What are you going to do [next]?

For me right now, I don't know what's next. And that's OK. That's OK, because I'm young and I have time to figure it out. And I'm grateful. I'm grateful to the people that I've met. I'm grateful to the agents that I worked with. I'm grateful for the experiences I was able to have these last four years. But at the same time, I just am also grateful that I don't have to do that anymore because it was in direct conflict with who I am as an individual, as a human being.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Silver Crown Royalties Inc. (SCRI:CBOE; SLCRF:OTCQX; QS0:FSE) announced record quarterly revenues in its financial results for the third quarter ending on September 30, 2024. Read more about the impressive growth in silver deliveries and how the company is strategically positioned for continued expansion.

Microsoft-owned OpenAI has announced the general availability of its latest text-generating model GPT-4, through its API.

While the U.S. Environmental Protection Agencys guideline for protecting the public from a toxic form of mercury is justifiable based on the latest scientific evidence, some children of women who consume large amounts of fish and seafood during pregnancy may be at special risk of neurological problems.

The nations health care industry has foundered in its ability to provide safe, high-quality care consistently to all Americans, says a new report from the Institute of Medicine of the National Academies. Reorganization and reform are urgently needed to fix what is now a disjointed and inefficient system.

One out of every four dogs and cats in the western world is now obese. Like humans, dogs and cats that are obese run a higher risk of developing diabetes, heart disease, or other health problems.

Government authorities in the United States and Canada should use the current Dietary Reference Intakes (DRIs) to update nutrition information on food and dietary supplement labels so that consumers can compare products more easily and make informed food choices based on the latest science, says a new report from the Institute of Medicine of the National Academies.

The National Academies today recommended guidelines for research involving human embryonic stem cells, and urged all institutions conducting such research to establish oversight committees to ensure that the new guidelines will be followed.

A growing amount of scientific evidence indicates that how much weight women gain during pregnancy and their starting weight at conception can affect their health and that of their babies, says a new report from the Institute of Medicine and the National Research Council.

The U.S. electric power delivery system is vulnerable to terrorist attacks that could cause much more damage to the system than natural disasters such as Hurricane Sandy, blacking out large regions of the country for weeks or months and costing many billions of dollars, says a newly released report by the National Research Council.

Today during the National Academy of Sciences 154th annual meeting, in her first speech to the members of the Academy, NAS President Marcia McNutt stressed the ongoing vitality of America’s scientific enterprise, and called on the country to strengthen its support for science and to continue to turn to science for solutions to the nation’s and the world’s most pressing challenges.

Although the process used to develop the Dietary Guidelines for Americans (DGA) has become more evidence-based since its inception more than 30 years ago, it is not currently positioned to effectively adapt to changes such as food diversity and chronic disease prevalence, while also ensuring the integrity of the process, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector, says a new report from the National Academies of Sciences, Engineering, and Medicine.

July 18 marks Nelson Mandela Day, which honors the legacy of the late President of South Africa and recognizes the nearly three decades that he spent in prison during apartheid. In accordance with the Nelson Mandela Rules (revised Standard Minimum Rules for the Treatment of Prisoners), adopted by the UN in 2015, this internationally recognized day is to be used to promote humane conditions of imprisonment and to raise awareness of prisoners as a continuous part of society.

Whether a patient has a safe place to live or healthy food to eat has an important influence on their health, but such nonmedical social needs have not traditionally been addressed in routine health care visits.

For severe acute pain due to surgeries and medical conditions, there is a lack of guidance on the appropriate type, strength, and amount of opioid medication that clinicians should prescribe to patients, says a new report from the National Academies of Sciences, Engineering, and Medicine.

A new report from the National Academies of Sciences, Engineering, and Medicine provides a blueprint and eight overarching strategies for improving health care for the approximately 100,000 people in the United States living with sickle cell disease (SCD).

Where needed to adhere to public health guidelines and mitigate the spread of COVID-19, authorities should use their discretion to minimize incarceration in prisons and jails — and facilitate testing, quarantine, social supports, and individualized reentry plans for those released, according to a new report from the National Academies of Sciences, Engineering, and Medicine.

New models for studying the human brain — human neural organoids, transplants, and chimeras — show promise for advancing understanding of the brain and laying the groundwork for new therapeutic approaches to brain diseases that have so far proved hard to treat, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Organizers of the recent Nobel Prize Summit shared a statement titled “Our Planet, Our Future - An Urgent Call for Action” — issued by the summit’s steering committee and co-signed by 126 Nobel laureates — with leaders of the G-7 countries and the U.N. secretary general, as well as other groups.

As methane emissions come under heightened global scrutiny, learn how a state-of-the-art satellite can pinpoint their sources and deliver the insights needed for targeted mitigation efforts

Two former high court judges - SN Shukla of the Allahabad High Court and Quddusi of the Odisha High Court - have been charged by the CBI in the case. The agency had produced intercepted phone calls between the two judges as part of its charge sheet filed last July. It had also named other people in the alleged bribery scandal.

BT Compute brings you a choice of data centre and expert services that enable you to deliver applications and services where and when you need them -- Global services delivered locally. Our hybrid cloud services blend intelligent network and compute resources giving you the IT infrastructure you need to adapt, quickly and cost effectively.

Liquid crystals are strange substances, both fish and fowl. They can flow like a liquid, but have the orderly molecular structure of a crystalline solid. And that internal structure can be changed by small cues from outside.

read more

Meta announced the LLaMA in February this year in several sizes (7B, 13B, 33B, and 65B parameters) so it can be used by a range of users and companies. At I/O 2023, Google also talked about multiple LLMs that are suited to companies of different sizes.

In today's computer chips, memory management is based on what computer scientists call the principle of locality: If a program needs a chunk of data stored at some memory location, it probably needs the neighboring chunks as well.

read more

Artificial intelligence (AI) based foundations models such as Meta's Llama 2 and OpenAI's GPT-4 are low on transparency, according to a global report.

Tech Mahindra expands partnership to deliver NGFW modernization solution with Cisco. The solution includes unified policy management, Talos threat intelligence integration, and comprehensive malware defense for network and endpoints.

The Desserts By Us cookie brand has its roots in the founder’s favorite childhood desserts.

Direct-store delivery can help snack, bakery manufacturers get their products into end-users’ hands faster.

If there’s one thing the last few months have shown us, it’s that business-as-usual can be uprooted without warning.

Efficiency is the name of the game across all aspects of the food industry. For snack and bakery companies managing varying degrees of their product distribution, including direct-store delivery (DSD) routes, streamlining operations can come in many forms, including new technologies.

The secondary packaging machine is suitable for snack, bakery, and other applications.

Experts from the flavor provider discuss the types and uses of vanilla.

An equipment update is helping to bring the artisan bread company into the modern age.

New Philadelphia Cheesecake Crumble are available in packs of two, convenient single-serve cups at retailers nationwide with a suggested retail price of $3.99.

The cream cheese brand transforms America’s favorite holiday dessert into this season’s “it” gift.

A leader from the company discussed automated tech and ongoing labor challenges.